179 related articles for article (PubMed ID: 21976680)
1. The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.
Shapira S; Kazanov D; Weisblatt S; Starr A; Arber N; Kraus S
J Biol Chem; 2011 Nov; 286(47):40548-55. PubMed ID: 21976680
[TBL] [Abstract][Full Text] [Related]
2. CD24 controls Src/STAT3 activity in human tumors.
Bretz NP; Salnikov AV; Perne C; Keller S; Wang X; Mierke CT; Fogel M; Erbe-Hofmann N; Schlange T; Moldenhauer G; Altevogt P
Cell Mol Life Sci; 2012 Nov; 69(22):3863-79. PubMed ID: 22760497
[TBL] [Abstract][Full Text] [Related]
3. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.
Salnikov AV; Bretz NP; Perne C; Hazin J; Keller S; Fogel M; Herr I; Schlange T; Moldenhauer G; Altevogt P
Br J Cancer; 2013 Apr; 108(7):1449-59. PubMed ID: 23511563
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
5. CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy.
Rostoker R; Ben-Shmuel S; Rashed R; Shen Orr Z; LeRoith D
Breast Cancer Res; 2016 May; 18(1):51. PubMed ID: 27179633
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel single chain fragment variable antibody targeting CD24-expressing cancer cells.
Eyvazi S; Kazemi B; Bandehpour M; Dastmalchi S
Immunol Lett; 2017 Oct; 190():240-246. PubMed ID: 28866120
[TBL] [Abstract][Full Text] [Related]
7. CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy.
Ni YH; Zhao X; Wang W
Curr Gene Ther; 2020; 20(2):109-126. PubMed ID: 32576128
[TBL] [Abstract][Full Text] [Related]
8. Cluster of differentiation 24 monoclonal antibody induces apoptosis in the osteosarcoma cells.
Zhang YH; Wang ZY; Hao FY; Zhang L
Eur Rev Med Pharmacol Sci; 2014; 18(14):2038-41. PubMed ID: 25027344
[TBL] [Abstract][Full Text] [Related]
9. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
[TBL] [Abstract][Full Text] [Related]
10. Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene.
Efrat S; Fusco-DeMane D; Lemberg H; al Emran O; Wang X
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3576-80. PubMed ID: 7724601
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint CD24 function on tumor and immunotherapy.
Huang S; Zhang X; Wei Y; Xiao Y
Front Immunol; 2024; 15():1367959. PubMed ID: 38487533
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.
Rappa G; Lorico A
Exp Cell Res; 2010 May; 316(9):1576-86. PubMed ID: 20074564
[TBL] [Abstract][Full Text] [Related]
13. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis.
Thomas S; Harding MA; Smith SC; Overdevest JB; Nitz MD; Frierson HF; Tomlins SA; Kristiansen G; Theodorescu D
Cancer Res; 2012 Nov; 72(21):5600-12. PubMed ID: 22926560
[TBL] [Abstract][Full Text] [Related]
14. Heparanase promotes glioma progression via enhancing CD24 expression.
Barash U; Spyrou A; Liu P; Vlodavsky E; Zhu C; Luo J; Su D; Ilan N; Forsberg-Nilsson K; Vlodavsky I; Yang X
Int J Cancer; 2019 Sep; 145(6):1596-1608. PubMed ID: 31032901
[TBL] [Abstract][Full Text] [Related]
15. CD24 blockade as a novel strategy for cancer treatment.
Wang Y; Yu H; Yu M; Liu H; Zhang B; Wang Y; Zhao S; Xia Q
Int Immunopharmacol; 2023 Aug; 121():110557. PubMed ID: 37379708
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis.
Kristiansen G; Machado E; Bretz N; Rupp C; Winzer KJ; König AK; Moldenhauer G; Marmé F; Costa J; Altevogt P
Lab Invest; 2010 Jul; 90(7):1102-16. PubMed ID: 20351695
[TBL] [Abstract][Full Text] [Related]
17. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer.
Vanrell L; Di Scala M; Blanco L; Otano I; Gil-Farina I; Baldim V; Paneda A; Berraondo P; Beattie SG; Chtarto A; Tenenbaum L; Prieto J; Gonzalez-Aseguinolaza G
Mol Ther; 2011 Jul; 19(7):1245-53. PubMed ID: 21364542
[TBL] [Abstract][Full Text] [Related]
18. CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.
Burgos-Ojeda D; Wu R; McLean K; Chen YC; Talpaz M; Yoon E; Cho KR; Buckanovich RJ
Mol Cancer Ther; 2015 Jul; 14(7):1717-27. PubMed ID: 25969154
[TBL] [Abstract][Full Text] [Related]
19. From mechanism to therapy: the journey of CD24 in cancer.
Zhao K; Wu C; Li X; Niu M; Wu D; Cui X; Zhao H
Front Immunol; 2024; 15():1401528. PubMed ID: 38881902
[TBL] [Abstract][Full Text] [Related]
20. Integrase-derived peptides together with CD24-targeted lentiviral particles inhibit the growth of CD24 expressing cancer cells.
Shapira S; Finkelshtein E; Kazanov D; Naftali E; Stepansky I; Loyter A; Elbirt D; Hay-Levy M; Brazowski E; Bedny F; Dekel R; Hershkovitz D; Blachar A; Wolf I; Arber N
Oncogene; 2021 Jun; 40(22):3815-3825. PubMed ID: 33958722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
